Table 3. Safety and feasibility data of different neoadjuvant regimen in NSCLC.
| Neoadjuvant regimen | No. of patients | TRAEs, n (%) | 3-4 irAEs, n (%) | Resectable patients, n (%) | Surgery delay, n (%) | Complications, n (%) | MPR, n (%) | pCR, n (%) | ORR, n (%) |
|---|---|---|---|---|---|---|---|---|---|
| ICI | 140 | 37 (26.4) | 11 (7.9) | 126 (90.0) | 2 (1.6) | 15 (11.9) | 50 (39.7) | 24 (19.0) | 25 (17.8) |
| Chem + ICI | 218 | 157 (72.0) | 81 (37.2) | 185 (84.9) | 0 (0) | 35 (18.9) | 126 (68.1) | 71 (38.4) | 118 (54.1) |
NSCLC, non-small-cell lung cancer; No., number of; TRAEs, treatment-related adverse events; irAEs, immune-related adverse events; MPR, major pathologic response; pCR, pathological complete response; ORR, objective response rate; ICI, immune checkpoint inhibitor; Chem, chemotherapy.